Coherus Oncology, Inc.
About Coherus Oncology, Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2018
- $0
- Net income
- $168.0M
- Total assets
- $258.3M
- Market cap
- $223.7M
- Gross margin
- 67.2%
- Operating margin
- -429.5%
- Net margin
- 398.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $42.2M
- Cost of revenue
- $13.8M
- Gross profit
- $28.4M
- Operating expenses
- $209.5M
- Operating income
- -$181.1M
- Income tax
- $0
- Net income
- $168.0M
- EPS (basic)
- $1.43
- EPS (diluted)
- $1.43
Balance sheet
- Total assets
- $258.3M
- Current assets
- $206.7M
- Total liabilities
- $197.3M
- Current liabilities
- $140.4M
- Shareholders’ equity
- $61.0M
Cash flow
- Operating cash flow
- -$138.5M
- Investing cash flow
- $375.1M
- Financing cash flow
- -$273.7M
- Net cash flow
- -$37.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $223.7M
- P/E ratio
- 1.0
- EPS (diluted)
- $1.43
- Shares outstanding
- 157.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 6, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $168.0M in FY2018.
- Revenue declined 87% from FY2021 to FY2025.
- Gross margin of 67.2%, net margin 398.4%.
- Trading 43% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 1.0.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Coherus Oncology, Inc..
Write a review
News about Coherus Oncology, Inc.
News & sentiment via Polygon.io
